Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bivalirudin in STEMI patients undergoing primary PCI
NCT00093184Phase 3Completed
- Sponsor
- The Medicines Company
- Start
- Apr 2004
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of bivalirudin in ST-segment elevation myocardial infarction (STEMI), sponsored by The Medicines Company. Primary endpoint: Reduction in bleeding complications. Started Apr 2004; status: completed.
02
Drugs
bivalirudin
03
Conditions
ST-segment elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT00093184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00093184.